mRNA-based dendritic cell vaccines

Expert Review of Vaccines

Volumn 14, Issue 2, 2014, Pages 161-176

  Benteyn, Daphné ^a   Heirman, Carlo ^a   Bonehill, Aude ^a   Thielemans, Kris ^a   Breckpot, Karine ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

Author keywords

cancer; cytotoxic T cell; dendritic cell; mRNA; tumor antigen

Indexed keywords

DENDRITIC CELL VACCINE; MESSENGER RNA; CANCER VACCINE; TUMOR ANTIGEN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; DNA MODIFICATION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; HUMAN; IMMUNOGENICITY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); TUMOR IMMUNITY; ACTIVE IMMUNOTHERAPY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; NEOPLASMS; T LYMPHOCYTE;

ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; RNA, MESSENGER; T-LYMPHOCYTES;

EID: 84921376995     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2014.957684     Document Type: Review

References (161)

1. Vineis P, Wild CP. Global cancer patterns: causes and prevention. Lancet 2014; 383(9916):549-57
2. Wayteck L, Breckpot K, Demeester J, et al. A personalized view on cancer immunotherapy. Cancer Lett 2013
3. Van Der Bruggen P, Zhang Y, Chaux P, et al. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev 2002;188:51-64
4. Anguille S, Smits EL, Lion E, et al. Clinical use of dendritic cells for cancer therapy. Lancet Oncol 2014;15(7):e257-67
5. Vacchelli E, Vitale I, Eggermont A, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2013;2(10):e25771
6. Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013;342(6165):1432-3
7. Pen JJ, Aerts JL, Liechtenstein T, et al. Manipulating immune regulatory pathways to enhance T cell stimulation. Immune response activation 2014; doi: 10.5772/57539
8. Maher J. Clinical immunotherapy of B-cell malignancy using CD19-Targeted CAR T-cells. Curr Gene Ther 2014;14(1):35-43
9. Van Lint S, Wilgenhof S, Heirman C, et al. Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. Cancer Immunol Immunother 2014;63(9):959-67
10. Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. J Exp Med 1973;137: 1142-62
11. Steinman RM. Dendritic cells: understanding immunogenicity. Eur J Immunol 2007;37(Suppl 1):S53-60
12. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature 2007; 449(7161):419-26
13. Schuler G, Steinman RM. Murine epidermal Langerhans cells mature into potent immunostimulatory dendritic cells in vitro. J Exp Med 1985;161(3):526-46
14. Mahnke K, Schmitt E, Bonifaz L, et al. Immature, but not inactive: the tolerogenic function of immature dendritic cells. Immunol Cell Biol 2002;80(5):477-83
15. Galluzzi L, Senovilla L, Vacchelli E, et al. Trial watch: dendritic cell-based interventions for cancer therapy. Oncoimmunology 2012;1(7):1111-34
16. Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer 2012;12(4):265-77
17. Dalod M, Chelbi R, Malissen B, Lawrence T. Dendritic cell maturation: functional specialization through signaling specificity and transcriptional programming. EMBO J 2014;33(10):1104-16
18. Sabado RL, Bhardwaj N. Directing dendritic cell immunotherapy towards successful cancer treatment. Immunotherapy 2010;2(1):37-56
19. Benencia F, Sprague L, McGinty J, et al. Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination. J Biomed Biotechnol 2012;2012:425-76
20. Trombetta ES, Mellman I. Cell biology of antigen processing in vitro and in vivo. Annu Rev Immunol 2005;23:975-1028
21. Collin M, McGovern N, Haniffa M. Human dendritic cell subsets. Immunology 2013;140(1):22-30
22. Nizzoli G, Krietsch J, Weick A, et al. Human CD1c+ dendritic cells secrete high levels of IL-12 and potently prime cytotoxic T-cell responses. Blood 2013;122(6):932-42
23. Mittag D, Proietto AI, Loudovaris T, et al. Human dendritic cell subsets from spleen and blood are similar in phenotype and function but modified by donor health status. J Immunol 2011;186(11):6207-17
24. Liu YJ. Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity. Cell 2001;106(3):259-62
25. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2(1):52-8
26. Tuyaerts S, Aerts JL, Corthals J, et al. Current approaches in dendritic cell generation and future implications for cancer immunotherapy. Cancer Immunol Immunother 2007;56:1513-37
27. Tacken PJ, de Vries IJM, Torensma R, Figdor CG. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting. Nat Rev Immunol 2007;7(10):790-802
28. Wilgenhof S, Van Nuffel AMT, Benteyn D, et al. A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients. Ann Oncol 2013; 24(10):2686-93
29. Wilgenhof S, Van Nuffel AM, Corthals J, et al. Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma. J Immunother 2011;34:448-56
30. Morse MA, Nair SK, Mosca PJ, et al. Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. Cancer Invest 2003;21(3):341-9
31. Caruso DA, Orme LM, Neale AM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro Oncol 2004;6(3): 236-46
32. Coosemans A, Wölfl M, Berneman ZN, et al. Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. Anticancer Res 2010;30(9):3709-14
33. Coosemans A, Vanderstraeten A, Tuyaerts S, et al. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in ovarian carcinoma and carcinosarcoma. Anticancer Res 2013;33(9): 3855-9
34. Van Tendeloo VF, Van de Velde A, Van Driessche A, et al. Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-Targeted dendritic cell vaccination. Proc Natl Acad Sci USA 2010;107:13824-9
35. Di Nicola M, Carlo-Stella C, Mortarini R, et al. Boosting T cell-mediated immunity to tyrosinase by vaccinia virus-Transduced, CD34(+)-derived dendritic cell vaccination: a phase I trial in metastatic melanoma. Clin Cancer Res 2004;10(16):5381-90
36. Baek S, Kim C-S, Kim S-B, et al. Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial. J Transl Med 2011;9:178
37. Mu LJ, Lazarova P, Gaudernack G, et al. Development of a clinical grade procedure for generation of mRNA transfected dendritic cells from purified frozen CD34 (+) blood progenitor cells. Int J Immunopathol Pharmacol 2004;17(3): 255-63
38. Hsu AK, Kerr BM, Jones KL, et al. RNA loading of leukemic antigens into cord blood-derived dendritic cells for immunotherapy. Biol Blood Marrow Transplant 2006;12(8):855-67
39. Heiser A, Coleman D, Dannull J, et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002;109(3):409-17
40. Anguille S, Lion E, Tel J, et al. Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential. PLoS One 2012;7(12):e51851
41. Mohamadzadeh M, Berard F, Essert G, et al. Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J Exp Med 2001;194(7):1013-20
42. Anguille S, Lion E, Van den Bergh J, et al. Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. Hum Vaccin Immunother 2013;9(9):1956-61
43. Ahn JS, Agrawal B. IL-4 is more effective than IL-13 for in vitro differentiation of dendritic cells from peripheral blood mononuclear cells. Int Immunol 2005; 17(10):1337-46
44. Bautista EM, Nfon C, Ferman GS, Golde WT. IL-13 replaces IL-4 in development of monocyte derived dendritic cells (MoDC) of swine. Vet Immunol Immunopathol 2007;115(1-2):56-67
45. Rosenzwajg M, Camus S, Guigon M, Gluckman JC. The influence of interleukin (IL)-4, IL-13, and Flt3 ligand on human dendritic cell differentiation from cord blood CD34+ progenitor cells. Exp Hematol 1998;26(1):63-72
46. Buelens C, Bartholomé EJ, Amraoui Z, et al. Interleukin-3 and interferon beta cooperate to induce differentiation of monocytes into dendritic cells with potent helper T-cell stimulatory properties. Blood 2002;99(3):993-8
47. Breckpot K, Corthals J, Bonehill A, et al. Dendritic cells differentiated in the presence of IFN-beta and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. J Leukoc Biol 2005;78:898-908
48. Renneson J, Salio M, Mazouz N, et al. Mature dendritic cells differentiated in the presence of interferon-beta and interleukin-3 prime functional antigen-specific CD8 T cells. Clin Exp Immunol 2005;139(3):468-75
49. Trakatelli M, Toungouz M, Blocklet D, et al. A new dendritic cell vaccine generated with interleukin-3 and interferon-beta induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients. Cancer Immunol Immunother 2006;55(4):469-74
50. Kvistborg P, Boegh M, Pedersen AW, et al. Fast generation of dendritic cells. Cell Immunol 2009;260(1):56-62
51. Ramadan G. Fast monocyte-derived dendritic cell-based immunotherapy. Methods Mol Biol 2014;1139:131-44
52. Jarnjak-Jankovic S, Hammerstad H, Saebøe-Larssen S, et al. A full scale comparative study of methods for generation of functional Dendritic cells for use as cancer vaccines. BMC Cancer 2007;7:119
53. Ponsaerts P, Van den Bosch G, Cools N, et al. Messenger RNA electroporation of human monocytes, followed by rapid in vitro differentiation, leads to highly stimulatory antigen-loaded mature dendritic cells. J Immunol 2002;169(4):1669-75
54. Villadangos JA. Hold on, the monocytes are coming!. Immunity 2007;26(4):390-2
55. Immune responses to autologous Langerhans-Type dendritic cells electroporated With mRNA encoding a tumor-Associated antigen in patients with malignancy: a single-Arm Phase I trial in Melanoma. Available from: http://clinicaltrials.gov/show/NCT01456104
56. CT7, MAGE-A3, and WT1 mRNA-electroporated autologous Langerhans-Type dendritic cells as consolidation for multiple myeloma patients undergoing autologous stem cell transplantation. Available from: http://clinicaltrials.gov/show/NCT01995708
57. Schlecht G, Garcia S, Escriou N, et al. Murine plasmacytoid dendritic cells induce effector/memory CD8+ T-cell responses in vivo after viral stimulation. Blood 2004; 104(6):1808-15
58. Tel J, Aarntzen EH, Baba T, et al. Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. Cancer Res 2013;73(3): 1063-75
59. Goyvaerts C, Kurt DG, Van Lint S, et al. Immunogenicity of targeted lentivectors. Oncotarget 2014;5(3):704-15
60. Ciré S, Da Rocha S, Yao R, et al. Immunization of mice with lentiviral vectors targeted to MHC class II+ cells is due to preferential transduction of dendritic cells in vivo. PLoS ONE 2014;9(7):e101644
61. Lou Y, Liu C, Kim GJ, et al. Plasmacytoid dendritic cells synergize with myeloid dendritic cells in the induction of antigen-specific antitumor immune responses. J Immunol 2007;178(3):1534-41
62. Cheever MA, Allison JP, Ferris AS, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15:5323-37
63. Overwijk WW, Wang E, Marincola FM, et al. Mining the mutanome: developing highly personalized Immunotherapies based on mutational analysis of tumors. J Immunother Cancer 2013;1:11
64. Kreiter S, Castle JC, Türeci O, Sahin U. Targeting the tumor mutanome for personalized vaccination therapy. Oncoimmunology 2012;1(5):768-9
65. Van Nuffel AM, Benteyn D, Wilgenhof S, et al. Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4(+) and CD8(+) T Cells in Melanoma Patients. Mol Ther 2012;20:1063-74
66. Breckpot K, Heirman C, Neyns B, Thielemans K. Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. J Gene Med 2004;6(11): 1175-88
67. Smits EL, Anguille S, Cools N, et al. Dendritic cell-based cancer gene therapy. Hum Gene Ther 2009;20(10):1106-18
68. Weide B, Garbe C, Rammensee H-G, Pascolo S. Plasmid DNA- and messenger RNA-based anti-cancer vaccination. Immunol Lett 2008;115(1):33-42
69. Diken M, Kreiter S, Selmi A, et al. Antitumor Vaccination with Synthetic mRNA: strategies for In Vitro and In Vivo Preclinical Studies. Methods Mol Biol 2013;969:235-46
70. Van Lint S, Heirman C, Thielemans K, Breckpot K. mRNA: from a chemical blueprint for protein production to an off-The-shelf therapeutic. Hum vaccin immunother 2013;9(2):265-74
71. Boczkowski D, Nair SK, Snyder D, Gilboa E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J Exp Med 1996; 184(2):465-72
72. Nair SK, Boczkowski D, Morse M, et al. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. Nat Biotechnol 1998;16(4):364-9
73. Diken M, Kreiter S, Selmi A, et al. Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation. Gene Ther 2011;18:702-8
74. Pascolo S. Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008;183(183):221-35
75. Van Tendeloo VF, Ponsaerts P, Lardon F, et al. Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood 2001;98(1):49-56
76. Tuyaerts S, Noppe SM, Corthals J, et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods 2002;264(1-2):135-51
77. Melhem NM, Gleason SM, Liu XD, Barratt-Boyes SM. High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-Type viral mRNA but not DNA. Clin Vaccine Immunol 2008;15(9):1337-44
78. De Temmerman M-L, Dewitte H, Vandenbroucke RE, et al. mRNA-Lipoplex loaded microbubble contrast agents for ultrasound-Assisted transfection of dendritic cells. Biomaterials 2011;32(34):9128-35
79. Probst J, Brechtel S, Scheel B, et al. Characterization of the ribonuclease activity on the skin surface. Genet Vaccines Ther 2006;4:4
80. De Haes W, Rejman J, Pollard C, et al. Lipoplexes carrying mRNA encoding Gag protein modulate dendritic cells to stimulate HIV-specific immune responses. Nanomedicine 2013;8(1):77-87
81. Dewitte H, Van Lint S, Heirman C, et al. The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-Triggered cancer immunotherapy. J Contr Release 2014.In press
82. Michiels A, Tuyaerts S, Bonehill A, et al. Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. Gene Ther 2005;12: 772-82
83. Van Meirvenne S, Straetman L, Heirman C , et al. Efficient genetic modification of murine dendritic cells by electroporation with mRNA. Cancer Gene Ther 2002;9(9): 787-97
84. Geiger C, Regn S, Weinzierl A, et al. A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. J Transl Med 2005;3:29
85. Landi A, Babiuk LA, van Drunen Littel-van den Hurk S. High transfection efficiency, gene expression, and viability of monocyte-derived human dendritic cells after nonviral gene transfer. J Leukoc Biol 2007;82(4):849-60
86. Dewitte H, Verbeke R, Breckpot K, et al. Choose your models wisely: how different murine bone marrow-derived dendritic cell protocols influence the success of nanoparticulate vaccines in vitro. J Control release 2014;doi: 10.1016/j. jconrel.2014.06.024
87. Van Meirvenne S, Dullaers M, Heirman C, et al. In vivo depletion of CD4+CD25+regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells. Mol Ther 2005;12(5):922-32
88. Markovic SN, Dietz AB, Greiner CW, et al. Preparing clinical-grade myeloid dendritic cells by electroporation-mediated transfection of in vitro amplified tumor-derived mRNA and safety testing in stage IV malignant melanoma. J Transl Med 2006;4:35
89. Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-b antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int 2011;79(11): 1236-43
90. Nirschl CJ, Drake CG. Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy. Clin Cancer Res 2013;19(18):4917-24
91. Kyte JA, Mu L, Aamdal S, et al. Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 2006;13:10:905-18
92. Dannull J, Su Z, Rizzieri D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005;115(12):3623-33
93. Benteyn D, Anguille S, Van Lint S, et al. Design of an optimized Wilms' tumor 1 (WT1) mRNA construct for enhanced WT1 expression and improved immunogenicity in vitro and in vivo. Mol Ther Nucleic Acids 2013;2:e134
94. Holtkamp S, Kreiter S, Selmi A, et al. Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells. Blood 2006;108(13):4009-17
95. Kuhn AN, Diken M, Kreiter S, et al. Determinants of intracellular RNA pharmacokinetics. RNA Biol 2011; 8(1):35-43
96. Pascolo S. Messenger RNA-based vaccines. Expert Opin Biol Ther 2004;4(8):1285-94
97. Schlake T, Thess A, Fotin-Mleczek M, Kallen KJ. Developing mRNA-vaccine technologies. RNA Biol 2012;9(11):1319-30
98. Guhaniyogi J, Brewer G. Regulation of mRNA stability in mammalian cells. Gene 2001;265(1-2):11-23
99. Manuvakhova M, Keeling K, Bedwell DM. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 2000;6(7):1044-55
100. Bonehill A, Heirman C, Thielemans K. Genetic approaches for the induction of a CD4+ T cell response in cancer immunotherapy. J Gene Med 2005;7(6): 686-95
101. Bonehill A, Heirman C, Tuyaerts S, et al. Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J Immunol 2004;172:6649-57
102. Su Z, Vieweg J, Weizer AZ, et al. Enhanced induction of telomerase-specific CD4(+) T cells using dendritic cells transfected with RNA encoding a chimeric gene product. Cancer Res 2002;62:5041-8
103. Kreiter S, Selmi A, Diken M, et al. Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals. J Immunol 2008;180: 309-18
104. De Keersmaecker B, Heirman C, Allard S, et al. Lumenal part of the DC-LAMP protein is not required for induction of antigen-specific T cell responses by means of antigen-DC-LAMP messenger RNA-electroporated dendritic cells. Hum Gene Ther 2010;21:479-85
105. Tran E, Turcotte S, Gros A, et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 2014;344(6184):641-5
106. Breckpot K, Escors D. Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. Endocr Metab Immune Disord Drug Targets 2009;9(4):328-43
107. Jonuleit H, Kühn U, Müller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol 1997;27(12):3135-42
108. De Vries IJ, Lesterhuis WJ, Scharenborg NM, et al. Maturation of Dendritic Cells Is a Prerequisite for Inducing Immune Responses in Advanced Melanoma Patients. Clin Cancer Res 2003;9:5091-100
109. Yamanaka R, Homma J, Yajima N, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005;11(11):4160-7
110. Draube A, Klein-González N, Mattheus S, et al. Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-Analysis. PLoS One 2011;6(4):e18801
111. Okada H, Kalinski P, Ueda R, et al. Induction of CD8+ T-cell responses against novel glioma-Associated antigen peptides and clinical activity by vaccinations with {alpha}-Type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in. J Clin Oncol 2011;29(3):330-6
112. Carreno BM, Becker-Hapak M, Huang A, et al. IL-12p70-producing patient DC vaccine elicits Tc1-polarized immunity. J Clin Invest 2013;123(8):3383-94
113. Napolitani G, Rinaldi A, Bertoni F, et al. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6(8): 769-76
114. Warger T, Osterloh P, Rechtsteiner G, et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006;108(2):544-50
115. Arce F, Kochan G, Breckpot K, et al. Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. Anticancer Agents Med Chem 2012;12(1):29-39
116. Aerts-Toegaert C, Heirman C, Tuyaerts S, et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur J Immunol 2007;37:686-95
117. Tuyaerts S, Van Meirvenne S, Bonehill A, et al. Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. J Leukoc Biol 2007;82(1):93-105
118. Dannull J, Nair S, Su Z, et al. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. Blood 2005;105(8):3206-13
119. Grünebach F, Kayser K, Weck MM, et al. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes. Cancer Gene Ther 2005;12(9):749-56
120. De Keersmaecker B, Heirman C, Corthals J, et al. The combination of 4-1BBL and CD40L strongly enhances the capacity of dendritic cells to stimulate HIV-specific T cell responses. J Leukoc Biol 2011;89(6): 989-99
121. Bontkes HJ, Kramer D, Ruizendaal JJ, et al. Dendritic cells transfected with interleukin-12 and tumor-Associated antigen messenger RNA induce high avidity cytotoxic T cells. Gene Ther 2007;14(4): 366-75
122. Bontkes HJ, Kramer D, Ruizendaal JJ, et al. Tumor associated antigen and interleukin-12 mRNA transfected dendritic cells enhance effector function of natural killer cells and antigen specific T-cells. Clin Immunol 2008;127(3):375-84
123. Dörrie J, Schaft N, Müller I, et al. Introduction of functional chimeric E/Lselectin by RNA electroporation to target dendritic cells from blood to lymph nodes. Cancer Immunol Immunother 2008;57(4): 467-77
124. Pen JJ, Keersmaecker BD, Heirman C, et al. Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. Gene Ther 2014; 21(3):262-71
125. Pruitt SK, Boczkowski D, de Rosa N, et al. Enhancement of anti-Tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. Eur J Immunol 2011;41(12):3553-63
126. Boczkowski D, Lee J, Pruitt S, Nair S. Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. Cancer Gene Ther 2009;16(12):900-11
127. Local modulation of immune receptors to enhance the response to dendritic cell vaccination in metastatic melanoma. Available from: http://clinicaltrials.gov/show/NCT01216436
128. Abdel-Wahab Z, Cisco R, Dannull J, et al. Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. J Surg Res 2005;124(2):264-73
129. DeBenedette MA, Calderhead DM, Tcherepanova IY, et al. Potency of mature CD40L RNA electroporated dendritic cells correlates with IL-12 secretion by tracking multifunctional CD8(+)/CD28(+) cytotoxic T-cell responses in vitro. J Immunother 2011;34(1):45-57
130. Bonehill A, Tuyaerts S, Van Nuffel AMT, et al. Enhancing the T-cell stimulatory capacity of human dendritic cells by co-electroporation with CD40L, CD70 and constitutively active TLR4 encoding mRNA. Mol Ther 2008;16:1170-80
131. Benteyn D, Van Nuffel AMT, Wilgenhof S, et al. Characterization of CD8+ T-cell responses in the peripheral blood and skin injection sites of melanoma patients treated with mRNA electroporated autologous dendritic cells (TriMixDC-MEL). Biomed Res Int 2013;2013:976383
132. Van Lint S, Goyvaerts C, Maenhout S, et al. Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. Cancer Res 2012;72(7):1661-71
133. Van Nuffel AM, Benteyn D, Wilgenhof S, et al. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2011
134. Bonehill A, Van Nuffel AMT, Corthals J, et al. Single-step antigen loading and activation of dendritic cells by mRNA electroporation for the purpose of therapeutic vaccination in melanoma patients. Clin Cancer Res 2009;15(10): 3366-75
135. Pen JJ, De Keersmaecker B, Maenhout SK, et al. Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. J Immunol 2013;191(4):1976-83
136. A study on the safety and immunogenicity of combined intradermal and intravenous administration of an autologous mRNA electroporated dendritic cell vaccine in patients with previously treated unresectable stage III or IV Melanoma. Available from: http://clinicaltrials.gov/show/NCT01066390
137. Oshita C, Takikawa M, Kume A, et al. Dendritic cell-based vaccination in metastatic melanoma patients: phase II clinical trial. Oncol Rep 2012;28(4):1131-8
138. Aarntzen EH, Schreibelt G, Bol K, et al. Vaccination with mRNA-electroporated dendritic cells induces robust tumor antigen-specific CD4+ and CD8+ T cells responses in stage III and IV melanoma patients. Clin Cancer Res 2012;18(19): 5460-70
139. Connolly NC, Whiteside TL, Wilson C, et al. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals. Clin Vaccine Immunol 2008;15(2):284-92
140. Grover A, Kim GJ, Lizée G, et al. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin Cancer Res 2006; 12(19):5801-8
141. Triozzi PL, Khurram R, Aldrich WA, et al. Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer. Cancer 2000;89(12):2646-54
142. Okada N, Tsujino M, Hagiwara Y, et al. Administration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens. Br J Cancer 2001;84(11): 1564-70
143. Eggert AA, Schreurs MW, Boerman OC, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res 1999;59(14):3340-5
144. Mullins DW, Sheasley SL, Ream RM, et al. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J Exp Med 2003; 198(7):1023-34
145. Celluzzi CM, Mayordomo JI, Storkus WJ, et al. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183(1): 283-7
146. Lesterhuis WJ, de Vries IJ, Schreibelt G, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res 2011; 17(17):5725-35
147. Van Nuffel AM, Benteyn D, Wilgenhof S, et al. Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunol Immunother 2012;61(7):1033-43
148. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363(8):711-23
149. Autologous TriMix-DC therapeutic vaccine in combination with ipilimumab in patients with previously treated unresectable stage III or IV melanoma (TriMix-Ipi). Available from: http://clinicaltrials.gov/show/NCT01302496
150. Neyns B, Wilgenhof S, Corthals J, et al. Phase II of autologous mRNA electroporated dendritic cells (TriMixDC-MEL) in combination with ipilimumab in patients with pretreated advanced melanoma. ASCO meeting (2014). J Clin Oncol 2014; 32(suppl):abstract 3014
151. Kreiter S, Selmi A, Diken M, et al. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Cancer Res 2010;70(22): 9031-40
152. Schuurhuis DH, Lesterhuis WJ, Kramer M, et al. Polyinosinic polycytidylic acid prevents efficient antigen expression after mRNA electroporation of clinical grade dendritic cells. Cancer Immunol Immunother 2009;58(7):1109-15
153. Rains N, Cannan RJ, Chen W, Stubbs RS. Development of a dendritic cell (DC)-based vaccine for patients with advanced colorectal cancer. Hepatogastroenterology 2001; 48(38):347-51
154. Nair SK, Morse M, Boczkowski D, et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-Transfected dendritic cells. Ann Surg 2002;235(4):540-9
155. Su Z, Dannull J, Heiser A, et al. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-Transfected dendritic cells. Cancer Res 2003;63(9):2127-33
156. Caruso D, Orme LM, Amor GM, et al. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. Cancer 2005;103(6): 1280-91
157. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-Transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol 2005; 174(6):3798-807
158. Mu LJ, Kyte JA, Kvalheim G, et al. Immunotherapy with allotumour mRNA-Transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005;93(7):749-56
159. Kyte JA, Kvalheim G, Lislerud K, et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells. Cancer Immunol Immunother 2007;56(5):659-75
160. Suso EM, Dueland S, Rasmussen AM, et al. hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes. Cancer Immunol Immunother 2011;60:809-18
161. Vik-Mo EO, Nyakas M, Mikkelsen BV, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-Transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother 2013;62(9):1499-509